Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum

Anna Isinger*, Misha Bhat, Ake Borg and Mef Nilbert

Author Affiliations

Department of Oncology, Institute of Clinical Sciences, Lund University, 221 85 Lund, Sweden

For all author emails, please log on.

BMC Cancer 2006, 6:64  doi:10.1186/1471-2407-6-64

Published: 15 March 2006

Abstract

Background

Development of multiple primary tumors is a hallmark of hereditary cancer. At least 1/10 of breast cancers and colorectal cancers occur because of heredity and recently the cell cycle kinase 2, CHEK2 1100delC allele has been identified at a particularly high frequency in families with hereditary breast and colorectal cancer.

Methods

We utilized the Southern Sweden population-based cancer registry to identify women with double primary breast and colorectal cancer and sequenced tumor material in order to assess the contribution of the CHEK2 1100delC to the development of such metachronous tumors.

Results

Among the 75 patients successfully analyzed, 2 (2.5%) carried the CHEK2 1100delC allele. which was not significantly different (p = 0.26) from the 1% (3/300) carriers identified in the control group.

Conclusion

In summary, our data suggest that the CHEK2 1100delC is not a major cause of double primary breast and colorectal cancer in Sweden, which suggests that this patient group should not routinely be screened for the CHEK2 1100delC variant.